絞り込み

16762

広告

院内トリアージ実施料の範囲を拡大へ (日経BP)

2020年4月8日、中央社会保険医療協議会(中医協)総会が開催され、新型コロナウイルス感染症に伴う医療保険制度の対応が議論された。 厚生労働省保険局医療課は、外...

  1. 「第4の携帯」楽天が船出 コロナで一部店...
  2. ペムブロリズマブのTMB高値既治療固形癌...
  3. 中等症の患者を集めて高次病院の負担軽減目...
  4. 令和2年3月末申請の収容定員の増加に係る...

ニュース一覧

Pazopanib, a promising option for the treatment of aggressive fibromatosis.

著者 Szucs Z , Messiou C , Wong HH , Hatcher H , Miah A , Zaidi S , van der Graaf WT , Judson I , Jones RL , Benson C
Anticancer Drugs.2017 Jan 17 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (9view , 0users)

Full Text Sources

Medical

Miscellaneous

Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of agents are used. Tyrosine kinase inhibitors have recently been reported to show useful activity. We reviewed our bi-institutional (Royal Marsden Hospital, Cambridge University Hospitals) experience with the tyrosine kinase inhibitor pazopanib in the treatment of progressing DT/AF. Eight patients with DT/AF were treated with pazopanib at Royal Marsden Hospital and Cambridge University Hospitals between June 2012 and June 2016. The median age of the patients was 37.5 (range: 27-60) years. The median duration of pazopanib treatment was 12 (range: 5-22) months and for three patients the treatment is ongoing. Three patients discontinued treatment early (patient preference, intolerable toxicity and logistical reasons, respectively). None of the patients showed radiological progression while on treatment, best responses according to Response Evaluation Criteria In Solid Tumors 1.1 were partial response in 3/8 and stable disease in 5/8 cases. Six patients derived clinical benefit from treatment in terms of improved function and/or pain reduction. Median progression-free survival was 13.5 (5-36) months. Only one patient experienced intolerable toxicity (grade 3 hypertension) leading to early treatment discontinuation. In our series of patients with DT/AF, pazopanib demonstrated important activity both in terms of symptom control (75%) and absence of radiological progression (100%). Results of ongoing confirmatory trials are eagerly awaited.
PMID: 28099210 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード